57 84

Cited 3 times in

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

DC FieldValueLanguage
dc.contributor.author심지영-
dc.contributor.author윤영원-
dc.date.accessioned2017-11-02T08:07:43Z-
dc.date.available2017-11-02T08:07:43Z-
dc.date.issued2017-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/154111-
dc.description.abstractBACKGROUND: Hypertension and dyslipidemia are major risk factors of cardiovascular disease (CVD) events. The objective of this study was to evaluate the efficacy and safety of the co-administration of fimasartan and rosuvastatin in patients with hypertension and hypercholesterolemia. METHODS: We conducted a randomized double-blind and parallel-group trial. Patients who met eligible criteria after 4 weeks of therapeutic life change were randomly assigned to the following groups. 1) co-administration of fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV), 2) fimasartan 120 mg (FMS) alone 3) rosuvastatin 20 mg (RSV) alone. Drugs were administered once daily for 8 weeks. RESULTS: Of 140 randomized patients, 135 for whom efficacy data were available were analyzed. After 8 weeks of treatment, the FMS/RSV treatment group showed greater reductions in sitting systolic (siSBP) and diastolic (siDBP) blood pressures than those in the group receiving RSV alone (both p < 0.001). Reductions in siSBP and siDBP were not significantly different between the FMS/RSV and FMS alone groups (p = 0.500 and p = 0.734, respectively). After 8 weeks of treatment, FMS/RSV treatment showed greater efficacy in percentage reduction of low-density lipoprotein cholesterol (LDL-C) level from baseline than that shown by FMS alone treatment (p < 0.001). The response rates of siSBP with FMS/RSV, FMS alone, and RSV alone treatments were 65.22, 55.56, and 34.09%, respectively (FMS/RSV vs. RSV, p = 0.006). The LDL-C goal attainment rates with FMS/RSV, RSV alone, and FMS alone treatments were 80.43%, 81.82%, and 15.56%, respectively (FMS/RSV vs. FMS, p < 0.001). Incidence of adverse drug reactions with FMS/RSV treatment was 8.33%, which was similar to those associated with FMS and RSV alone treatments. CONCLUSION: This study demonstrated that the co-administration of fimasartan and rosuvastatin to patients with both hypertension and hypercholesterolemia was efficacious and safe.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherBioMed Central-
dc.relation.isPartOfBMC Pharmacology & Toxicology-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAngiotensin II Type 1 Receptor Blockers/administration & dosage-
dc.subject.MESHAngiotensin II Type 1 Receptor Blockers/adverse effects-
dc.subject.MESHAngiotensin II Type 1 Receptor Blockers/therapeutic use*-
dc.subject.MESHAnticholesteremic Agents/administration & dosage-
dc.subject.MESHAnticholesteremic Agents/adverse effects-
dc.subject.MESHAnticholesteremic Agents/therapeutic use*-
dc.subject.MESHBiphenyl Compounds/administration & dosage-
dc.subject.MESHBiphenyl Compounds/adverse effects-
dc.subject.MESHBiphenyl Compounds/therapeutic use*-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHHypercholesterolemia/complications-
dc.subject.MESHHypercholesterolemia/drug therapy*-
dc.subject.MESHHypertension/complications-
dc.subject.MESHHypertension/drug therapy*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPyrimidines/administration & dosage-
dc.subject.MESHPyrimidines/adverse effects-
dc.subject.MESHPyrimidines/therapeutic use*-
dc.subject.MESHRosuvastatin Calcium/administration & dosage-
dc.subject.MESHRosuvastatin Calcium/adverse effects-
dc.subject.MESHRosuvastatin Calcium/therapeutic use*-
dc.subject.MESHTetrazoles/administration & dosage-
dc.subject.MESHTetrazoles/adverse effects-
dc.subject.MESHTetrazoles/therapeutic use*-
dc.subject.MESHYoung Adult-
dc.titleThe efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia-
dc.typeArticle-
dc.publisher.locationEngland-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorMoo-Yong Rhee-
dc.contributor.googleauthorTaehoon Ahn-
dc.contributor.googleauthorKiyuk Chang-
dc.contributor.googleauthorShung Chull Chae-
dc.contributor.googleauthorTae-Hyun Yang-
dc.contributor.googleauthorWan Joo Shim-
dc.contributor.googleauthorTae Soo Kang-
dc.contributor.googleauthorJae-Kean Ryu-
dc.contributor.googleauthorDeuk-Young Nah-
dc.contributor.googleauthorTae-Ho Park-
dc.contributor.googleauthorIn-Ho Chae-
dc.contributor.googleauthorSeung Woo Park-
dc.contributor.googleauthorHae-Young Lee-
dc.contributor.googleauthorSeung-Jea Tahk-
dc.contributor.googleauthorYoung Won Yoon-
dc.contributor.googleauthorChi Young Shim-
dc.contributor.googleauthorDong-Gu Shin-
dc.contributor.googleauthorHong Seog Seo-
dc.contributor.googleauthorSung Yun Lee-
dc.contributor.googleauthorDoo Il Kim-
dc.contributor.googleauthorJun Kwan-
dc.contributor.googleauthorSeung-Jae Joo-
dc.contributor.googleauthorMyung Ho Jeong-
dc.contributor.googleauthorJin-Ok Jeong-
dc.contributor.googleauthorKi Chul Sung-
dc.contributor.googleauthorSeok Yeon Kim-
dc.contributor.googleauthorSang-Hyun Kim-
dc.contributor.googleauthorKook-Jin Chun-
dc.contributor.googleauthorDong Joo Oh-
dc.identifier.doi10.1186/s40360-016-0112-7-
dc.contributor.localIdA02580-
dc.contributor.localIdA02213-
dc.relation.journalcodeJ03069-
dc.identifier.eissn2050-6511-
dc.relation.journalsince2012-
dc.identifier.pmid28057081-
dc.subject.keywordFimasartan-
dc.subject.keywordHypercholesterolemia-
dc.subject.keywordHypertension-
dc.subject.keywordRosuvastatin-
dc.contributor.alternativeNameShim, Chi Young-
dc.contributor.alternativeNameYoon, Young Won-
dc.contributor.affiliatedAuthorYoon, Young Won-
dc.contributor.affiliatedAuthorShim, Chi Young-
dc.citation.titleBMC Pharmacology & Toxicology-
dc.citation.volume18-
dc.citation.number2-
dc.citation.startPage1-
dc.citation.endPage11-
dc.identifier.bibliographicCitationBMC Pharmacology & Toxicology, Vol.18(2) : 1-11, 2017-
dc.date.modified2017-11-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.